Resources for Food and Drug Administration (FDA)

Critics question FDA, U.S. Customs handling of Ranbaxy case

www.nj.com

For two and a half years, the Food and Drug Administration collected evidence that Ranbaxy Laboratories, India's largest generic drugmaker, may have lied about the quality of medicines and chemicals it sent to the U.S. Regulators inspected Ranbaxy plants in India, subpoenaed records, visited warehouses in Uganda and Nigeria, and FBI agents raided the company's offices in Plainsboro and plant in New Brunswick.

This month, federal prosecutors said in court papers that the drugmaker's "violations have resulted and continue to result" in the importation of an unspecified amount of adulterated and misbranded medication.

Yet, Ranbaxy continues to export medicines to the U.S. to treat everything from cholesterol to seizures -- and this year, alone, won the right to sell 11 different drugs in the U.S. from the same regulators investigating the alleged production problems in India.

View the Resource

Share or bookmarklet this web page at: